Answers are grounded in this paper and cite their sources.
T cell-engaging bispecific antibodies such as teclistamab represent an important new treatment modality for multiple myeloma and other blood cancers. This study evaluates the real-world safety and efficacy of teclistamab, including its activity in populations not represented in the initial phase I/II study, and identifies clinical variables associated with treatment response. See related commentary by Zweegman et al., p. 542.
No takes yet. Share an insight, caveat, or question.
Razzo et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: